FDA Grants Emergency Use Authorization for Zoetis' Simparica Trio Against New World Screwworm
ZTS is trading near its 52-week low of $71.45 (5.6% above the low).
Summary
Zoetis received FDA Emergency Use Authorization for Simparica Trio to treat New World screwworm infestations in dogs and puppies. This is a new regulatory milestone that expands the product's label into an emerging disease area, driven by recent state orders requiring treatment for cross-border animal movement. The EUA provides a first-line treatment option in a public health emergency, potentially boosting near-term demand for the franchise. This follows a difficult Q2 with flat revenue and a 10% guidance cut, so the news offers a positive offset. Watch for any subsequent state or federal procurement orders tied to screwworm response.
At the time of this announcement, ZTS was trading at $75.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $31.2B. The 52-week trading range was $71.45 to $160.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.